Skip to main content
Fig. 5 | Journal of Hematology & Oncology

Fig. 5

From: Prognostic and therapeutic value of disruptor of telomeric silencing-1-like (DOT1L) expression in patients with ovarian cancer

Fig. 5

Knocking down of DOT1L decreases the expression of CDK6 and cyclin D3 in ovarian cancer cells. Western blotting confirmed decrease of corresponding G1 arrest proteins, CDK6, and cyclin D3 protein levels in SK-OV-3 cells and TOV21G cells knocking down of DOT1L with shDOT1L shRNAs (a) and DOT1L inhibitor, SGC0946 (b). c and d Densitometric analysis of the Western blot. Data shown are mean±SD and a two-tailed Mann-Whitney test was used for statistical analysis (P < 0.05). GAPDH or H3 was loading as control

Back to article page